Patents by Inventor Todd Bosanac

Todd Bosanac has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Rho kinase inhibitors
    Patent number: 10624882
    Abstract: Disclosed are novel substituted 2H-isoquinolin-1-one and 3H-quinazolin-4-one derivatives useful as inhibitors of Rho kinase and for treating a variety of diseases and disorders that are mediated or sustained through the activity of Rho kinase, including cardiovascular diseases, pharmaceutical compositions comprising such compounds, methods for using such compounds and processes for making such compounds.
    Type: Grant
    Filed: December 29, 2017
    Date of Patent: April 21, 2020
    Assignee: Aerie Pharmaceuticals, Inc.
    Inventors: Todd Bosanac, John David Ginn, Eugene Richard Hickey, Thomas Martin Kirrane, Jr., Weimin Liu, Anthony S. Prokopowicz, Sabine K. Schlyer, Cheng-Kon Shih, Roger John Snow, Michael Robert Turner, Frank Wu, Erick Richard Young
  • Isoquinolones as BTK inhibitors
    Patent number: 10570118
    Abstract: The present invention encompasses compounds of the formula (I) wherein the groups R1, R2, R3, R4 and R5 are defined herein, which are suitable for the treatment of diseases related to Bruton's tyrosine kinase (BTK), and processes for making these compounds, pharmaceutical preparations containing these compounds, and their methods of use.
    Type: Grant
    Filed: January 12, 2017
    Date of Patent: February 25, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Todd Bosanac, Joerg Bentzien, Michael Jason Burke, Darren Todd DiSalvo, Wang Mao, Fariba Soleymanzadeh, John A. Westbrook, Zhaoming Xiong
  • HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS
    Publication number: 20200055843
    Abstract: The present invention encompasses compounds of the formula (I) wherein the groups R1, Cy and Y are defined herein, which are suitable for the treatment of diseases related to BTK, and processes for making these compounds, pharmaceutical preparations containing these compounds, and their methods of use.
    Type: Application
    Filed: August 29, 2019
    Publication date: February 20, 2020
    Inventors: Todd BOSANAC, Joerg BENTZIEN, Michael Jason BURKE, Ryan Michael FRYER, Eric Thomas LARSON, Wang MAO, Bryan Patrick MCKIBBEN, Yue SHEN, Fariba SOLEYMANZADEH, Matt Aaron TSCHANTZ
  • NOVEL THIENOTHIOPHENE COMPOUNDS FOR LONG-ACTING INJECTABLE COMPOSITIONS AND RELATED METHODS
    Publication number: 20200017529
    Abstract: The present invention provides compounds useful for the treatment of opioid dependence, alcohol dependence, alcohol use disorder, or the prevention of relapse to opioid dependence in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein.
    Type: Application
    Filed: July 11, 2019
    Publication date: January 16, 2020
    Inventors: Brian M. Aquila, Hoan Huynh, Lewis D. Pennington, Ingo Mugge, Baudouin Gerard, Markus Haeberlein, Roman A. Valiulin, Julius F. Remenar, Demetri T. Moustakas, Thomas Andrew Wynn, Todd Bosanac
  • NOVEL NAPHTHYLENYL COMPOUNDS FOR LONG-ACTING INJECTABLE COMPOSITIONS AND RELATED METHODS
    Publication number: 20200016151
    Abstract: The present invention provides compounds useful for the treatment of opioid dependence, alcohol dependence, alcohol use disorder, or the prevention of relapse to opioid dependence in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein.
    Type: Application
    Filed: July 11, 2019
    Publication date: January 16, 2020
    Inventors: Brian M. Aquila, Hoan Huynh, Lewis D. Pennington, Ingo Mugge, Baudouin Gerard, Markus Haeberlein, Roman A. Valiulin, Julius F. Remenar, Demetri T. Moustakas, Thomas Andrew Wynn, Todd Bosanac
  • HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS
    Publication number: 20190263828
    Abstract: The present invention encompasses compounds of the formula (I) wherein the groups A and B are defined herein, which are suitable for the treatment of diseases related to Vanin, and processes for making these compounds, pharmaceutical preparations containing these compounds, and their methods of use.
    Type: Application
    Filed: May 13, 2019
    Publication date: August 29, 2019
    Inventors: Todd BOSANAC, Michael J. BURKE, Brian Nicholas COOK, Darren Todd DISALVO, Thomas Martin KIRRANE, JR., Yue SHEN
  • Heteroaromatic compounds as Vanin inhibitors
    Patent number: 10364255
    Abstract: The present invention encompasses compounds of the formula (I) wherein the groups A and B are defined herein, which are suitable for the treatment of diseases related to Vanin, and processes for making these compounds, pharmaceutical preparations containing these compounds, and their methods of use.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: July 30, 2019
    Assignee: Boehringer Ingleheim International GmbH
    Inventors: Todd Bosanac, Michael J. Burke, Brian Nicholas Cook, Darren Todd Disalvo, Thomas Martin Kirrane, Jr., Yue Shen
  • HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS
    Publication number: 20190112302
    Abstract: The present invention encompasses compounds of the formula (I) wherein the groups A, Cy, X1 and Y are defined herein, which are suitable for the treatment of diseases related to BTK, process of making, pharmaceutical preparations which contain compounds and their methods of use.
    Type: Application
    Filed: October 15, 2018
    Publication date: April 18, 2019
    Inventors: Joerg BENTZIEN, Angela Kay BERRY, Todd BOSANAC, Michael Jason BURKE, Darren Todd DISALVO, Joshua Courtney HORAN, Shuang LIANG, Can MAO, Wang MAO, Yue SHEN, Fariba SOLEYMANZADEH, Renee M. ZINDELL
  • HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS
    Publication number: 20190092759
    Abstract: The present invention encompasses compounds of the formula (I) wherein the groups R1, Cy and Y are defined herein, which are suitable for the treatment of diseases related to BTK, and processes for making these compounds, pharmaceutical preparations containing these compounds, and their methods of use.
    Type: Application
    Filed: September 21, 2018
    Publication date: March 28, 2019
    Inventors: Todd BOSANAC, Joerg BENTZIEN, Michael Jason BURKE, Ryan Michael FRYER, Eric Thomas LARSON, Wang MAO, Bryan Patrick MCKIBBEN, Yue SHEN, Fariba SOLEYMANZADEH, Matt Aaron TSCHANTZ
  • ISOQUINOLONES AS BTK INHIBITORS
    Publication number: 20190023686
    Abstract: The present invention encompasses compounds of the formula (I) wherein the groups R1, R2, R3, R4 and R5 are defined herein, which are suitable for the treatment of diseases related to Bruton's tyrosine kinase (BTK), and processes for making these compounds, pharmaceutical preparations containing these compounds, and their methods of use.
    Type: Application
    Filed: January 12, 2017
    Publication date: January 24, 2019
    Inventors: Todd BOSANAC, Joerg BENTZIEN, Michael Jason BURKE, Darren Todd DISALVO, Wang MAO, Fariba SOLEYMANZADEH, John A. WESTBROOK, Zhaoming XIONG
  • HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS
    Publication number: 20180354968
    Abstract: The present invention encompasses compounds of the formula (I) wherein the groups A and B are defined herein, which are suitable for the treatment of diseases related to Vanin, and processes for making these compounds, pharmaceutical preparations containing these compounds, and their methods of use.
    Type: Application
    Filed: June 8, 2018
    Publication date: December 13, 2018
    Inventors: Todd BOSANAC, Michael J. BURKE, Brian Nicholas COOK, Darren Todd DISALVO, Thomas Martin KIRRANE, JR., Yue SHEN
  • RHO KINASE INHIBITORS
    Publication number: 20180344723
    Abstract: Disclosed are novel substituted 2H-isoquinolin-1-one and 3H-quinazolin-4-one derivatives useful as inhibitors of Rho kinase and for treating a variety of diseases and disorders that are mediated or sustained through the activity of Rho kinase, including cardiovascular diseases, pharmaceutical compositions comprising such compounds, methods for using such compounds and processes for making such compounds.
    Type: Application
    Filed: December 29, 2017
    Publication date: December 6, 2018
    Inventors: Todd Bosanac, John David Ginn, Eugene Richard Hickey, Thomas Martin Kirrane, JR., Weimin Liu, Anthony S. Prokopowicz, Sabine K. Schlyer, Cheng-Kon Shih, Roger John Snow, Michael Robert Turner, Frank Wu, Erick Richard Young
  • Heteroaromatic compounds as BTK inhibitors
    Patent number: 10138229
    Abstract: The present invention encompasses compounds of the formula (I) wherein the groups A, Cy, X1 and Y are defined herein, which are suitable for the treatment of diseases related to BTK, process of making, pharmaceutical preparations which contain compounds and their methods of use.
    Type: Grant
    Filed: November 16, 2017
    Date of Patent: November 27, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Joerg Bentzien, Angela Kay Berry, Todd Bosanac, Michael Jason Burke, Darren Todd Disalvo, Joshua Courtney Horan, Shuang Liang, Can Mao, Wang Mao, Yue Shen, Fariba Soleymanzadeh, Renee M. Zindell
  • HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS
    Publication number: 20180222893
    Abstract: The present invention encompasses compounds of the formula (I) wherein the groups R1, Cy and Y are defined herein, which are suitable for the treatment of diseases related to BTK, and processes for making these compounds, pharmaceutical preparations containing these compounds, and their methods of use.
    Type: Application
    Filed: April 9, 2018
    Publication date: August 9, 2018
    Inventors: Todd BOSANAC, Joerg BENTZIEN, Michael Jason BURKE, Ryan Michael FRYER, Eric Thomas LARSON, Wang MAO, Bryan Patrick MCKIBBEN, Yue SHEN, Fariba SOLEYMANZADEH, Matt Aaron TSCHANTZ
  • Heteroaromatic compounds as BTK inhibitors
    Patent number: 9975882
    Abstract: The present invention encompasses compounds of the formula (I) wherein the groups R1, Cy and Y are defined herein, which are suitable for the treatment of diseases related to BTK, and processes for making these compounds, pharmaceutical preparations containing these compounds, and their methods of use.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: May 22, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Todd Bosanac, Joerg Bentzien, Michael Jason Burke, Ryan Michael Fryer, Eric Thomas Larson, Wang Mao, Bryan Patrick McKibben, Yue Shen, Fariba Soleymanzadeh, Matt Aaron Tschantz
  • HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS
    Publication number: 20180086748
    Abstract: The present invention encompasses compounds of the formula (I) wherein the groups A, Cy, X1 and Y are defined herein, which are suitable for the treatment of diseases related to BTK, process of making, pharmaceutical preparations which contain compounds and their methods of use.
    Type: Application
    Filed: November 16, 2017
    Publication date: March 29, 2018
    Inventors: Joerg BENTZIEN, Angela Kay BERRY, Todd BOSANAC, Michael Jason BURKE, Darren Todd DISALVO, Joshua Courtney HORAN, Shuang LIANG, Can MAO, Wang MAO, Yue SHEN, Fariba SOLEYMANZADEH, Renee M. ZINDELL
  • HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS
    Publication number: 20180030037
    Abstract: The present invention encompasses compounds of the formula (I) wherein the groups R1, Cy and Y are defined herein, which are suitable for the treatment of diseases related to BTK, and processes for making these compounds, pharmaceutical preparations containing these compounds, and their methods of use.
    Type: Application
    Filed: October 12, 2017
    Publication date: February 1, 2018
    Inventors: Todd BOSANAC, Joerg BENTZIEN, Michael Jason BURKE, Ryan Michael FRYER, Eric Thomas LARSON, Wang MAO, Bryan Patrick MCKIBBEN, Yue SHEN, Fariba SOLEYMANZADEH, Matt Aaron TSCHANTZ
  • Pyrazole compounds as BTK inhibitors
    Patent number: 9828364
    Abstract: The present invention encompasses compounds of the formula (I) wherein the groups R1, Cy, and Y are defined herein, which are suitable for the treatment of diseases related to BTK, process of making, pharmaceutical preparations which contain compounds and their methods of use.
    Type: Grant
    Filed: January 23, 2015
    Date of Patent: November 28, 2017
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Joerg Bentzien, Angela Kay Berry, Todd Bosanac, Michael Jason Burke, Darren Todd Disalvo, Can Mao, Wang Mao, Yue Shen
  • Heteroaromatic compounds as BTK inhibitors
    Patent number: 9815822
    Abstract: The present invention encompasses compounds of the formula (I) wherein the groups R1, Cy and Y are defined herein, which are suitable for the treatment of diseases related to BTK, and processes for making these compounds, pharmaceutical preparations containing these compounds, and their methods of use.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: November 14, 2017
    Assignee: Boehringer Ingelheim Internatinal GmbH
    Inventors: Todd Bosanac, Joerg Bentzien, Michael Jason Burke, Ryan Michael Fryer, Eric Thomas Larson, Wang Mao, Bryan Patrick McKibben, Yue Shen, Fariba Soleymanzadeh, Matt Aaron Tschantz
  • HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS
    Publication number: 20170320867
    Abstract: The present invention encompasses compounds of the formula (I) wherein the groups A, Cy, X1 and Y are defined herein, which are suitable for the treatment of diseases related to BTK, process of making, pharmaceutical preparations which contain compounds and their methods of use.
    Type: Application
    Filed: July 27, 2017
    Publication date: November 9, 2017
    Inventors: Joerg Martin BENTZIEN, Angela Kay BERRY, Todd BOSANAC, Michael Jason BURKE, Darren Todd DISALVO, Joshua Courtney HORAN, Shuang LIANG, Can MAO, Wang MAO, Yue SHEN, Fariba SOLEYMANZADEH, Renee M. ZINDELL